Holy Young BioMedical

Holy Young BioMedical Co., Ltd. (HYBMC) is a Taiwan-based medical device and pharmaceutical distribution company established in December 2023 as a strategic spin-off from Holy Stone Healthcare. The company focuses on the commercialization and distribution of high-quality medical products, particularly hyaluronic acid-based medical devices developed by its Swiss-based subsidiary, MDT Int'l SA. Holy Young BioMedical's proprietary product portfolio includes RenehaVis™ for knee osteoarthritis, SportVis™ for tendon and ligament injuries, TRUD™ for ulcerative colitis, and GAF™ for anal mucosal lesions. Additionally, the company serves as an exclusive distributor in Taiwan for several international healthcare brands, including Qiagen's QuantiFERON®-TB Gold Plus, MediWound's NexoBrid® for burn care, and products from Arkopharma and Kenei Pharmaceutical.